-
Product Insights
NewGastritis – Drugs In Development, 2024
Empower your strategies with our Gastritis – Drugs In Development, 2024 report and make more profitable business decisions. Gastritis is characterized by inflammation or swelling of the lining of the stomach. Acute gastritis lasts for a short period of time while chronic gastritis lasts for a long period of time (months to years). Gastritis can be caused by medications such as ibuprofen, aspirin, or naproxen on long periods of consumption; excess intake of alcohol; Helicobacter pylori infection; certain autoimmune disorders; bile...
-
Product Insights
NewBacterial Sepsis – Drugs In Development, 2024
Empower your strategies with our Bacterial Sepsis – Drugs In Development, 2024 report and make more profitable business decisions. Infection caused by bacteria known as bacterial sepsis. Sepsis is an emergency condition when existing infections in the body are triggered or body’s extreme response to an infection. Sepsis can result in multi organ damage and septic shock. It is also referred to as blood poisoning and septicemia. Flu, chest pain, paleness or bluish grey coloration of skin, rashes, SOB, fever, change...
-
Product Insights
NewNeisseria gonorrhoeae Infections – Drugs In Development, 2024
Empower your strategies with our Neisseria gonorrhoeae Infections – Drugs In Development, 2024 report and make more profitable business decisions. Neisseria gonorrhoeae, the bacterium accountable for the sexually transmitted infection (STI) gonorrhea, is a notable public health issue causing substantial global morbidity in both resource-rich and resource-poor nations. The diagnosis and treatment of this infection entail considerable financial expenditures each year. Similar to other sexually transmitted infections (STIs), gonorrhea has a disproportionate impact on young adults. The obligate human pathogen N....
-
Product Insights
NewHelicobacter pylori Infections – Drugs In Development, 2024
Empower your strategies with our Helicobacter pylori Infections – Drugs In Development, 2024 report and make more profitable business decisions. Helicobacter pylori (H. pylori) infection occurs when the Helicobacter pylori (H. pylori) bacteria infect the stomach, typically during childhood. A leading cause of stomach ulcers, this infection is asymptomatic for many, with over half of the global population potentially affected. Recognition often arises when peptic ulcer symptoms manifest, prompting healthcare providers to test for H. pylori. Peptic ulcers, affecting the stomach...
-
Product Insights
NewSinusitis – Drugs In Development, 2024
Empower your strategies with our Sinusitis – Drugs In Development, 2024 report and make more profitable business decisions. Sinusitis is characterized by inflammation of the sinuses. This inflammation usually stems from a viral or bacterial infection or from an allergy. Symptoms include congestion and obstruction in the nose, pain, tenderness, hyposmia, halitosis, cough, toothache, headache, and pain over the cheeks just below the eyes. Risk factors include asthma, nasal passage abnormality, immune system disorder such as HIV/AIDS or cystic fibrosis, and...
-
Product Insights
NewRhinosinusitis – Drugs In Development, 2024
Empower your strategies with our Rhinosinusitis – Drugs In Development, 2024 report and make more profitable business decisions. Rhinosinusitis is a condition that affects the nasal and sinus mucosa, causing inflammation and symptoms such as nasal congestion, discharge, pain, and loss of smell. It can be classified into acute or chronic, depending on the duration of the illness. Acute rhinosinusitis usually lasts less than four weeks and is often caused by viral or bacterial infections. Chronic rhinosinusitis lasts more than 12...
-
Product Insights
NewKlebsiella Infections – Drugs In Development, 2024
Empower your strategies with our Klebsiella Infections – Drugs In Development, 2024 report and make more profitable business decisions. Klebsiella infections are caused by bacteria of the genus Klebsiella, with K. pneumoniae being the most common species associated with human infections. These bacteria are part of the normal flora in the human digestive tract and respiratory system but can cause various infections, especially in individuals with weakened immune systems or underlying health conditions. Klebsiella infections can manifest in different parts of...
-
Product Insights
NewEscherichia coli Infections – Drugs In Development, 2024
Empower your strategies with our Escherichia coli Infections – Drugs In Development, 2024 report and make more profitable business decisions. Escherichia coli (E. coli) bacteria normally live in the intestines of healthy people and animals. E. coli infections are caused by coming into contact with the feces of humans or animals, or eating or drinking contaminated food or beverage. Symptoms include diarrhea, which may range from mild and watery to severe and bloody; abdominal cramping; pain or tenderness; nausea; and vomiting....
-
Product Insights
NewKlebsiella pneumoniae Infections – Drugs In Development, 2024
Empower your strategies with our Klebsiella pneumoniae Infections – Drugs In Development, 2024 report and make more profitable business decisions. Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs, and is very common in patients with underlying diseases like diabetes, chronic lung disease, and alcoholism. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune systems. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever,...